Germ Cell Tumors Clinical Trials

A listing of Germ Cell Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1052 clinical trials
None
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

melanoma skin
immunomodulators
progressive disease
erbb2
squamous cell carcinoma of head and neck
  • 12 views
  • 06 Aug, 2021
  • 68 locations
None
Study of INBRX-105 in Patients With Solid Tumors

This is a first-in-human, open-label, nonrandomized, four-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor …

lymphoma
pd-l1
squamous cell carcinoma of head and neck
immunohistochemistry
kidney function test
  • 49 views
  • 31 Jul, 2021
  • 9 locations
None
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma). Subjects will be treated with IV pembrolizumab every 3 weeks and 1 capsule twice daily of MRx0518. …

pd-l1
progressive disease
bladder cancer
kidney cancer
monoclonal antibodies
  • 20 views
  • 02 Feb, 2021
  • 5 locations
None
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

lymphoma
cancer treatment
psychiatric illness
chemotherapy regimen
hepatitis
  • 26 views
  • 22 Aug, 2021
  • 5 locations
None
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would be with Pembrolizumab or Nivolumab monotherapy, who meet eligibility …

gastric adenocarcinoma
metastatic cancer
sulfonylureas
progressive disease
squamous cell carcinoma of head and neck
  • 0 views
  • 25 Jan, 2021
  • 1 location
None
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors

ct scan
progressive disease
squamous cell carcinoma of head and neck
cancer
medi4736
  • 52 views
  • 31 Oct, 2021
  • 12 locations
None
DNX-2440 for Resectable Colorectal Liver Metastasis

The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal ( 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor …

metastasis
gastrointestinal stromal tumor
cancer
chemotherapy regimen
stromal tumor
  • 0 views
  • 21 Jul, 2021
  • 1 location
None
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver Gastrointestinal Endocrine and Skin Toxicity

"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single agent PD1/L1 inhibitor; (2) PD1/L1 inhibitor plus CTLA4 inhibitor; (3) platinum-based chemotherapy + PD1/L1 inhibitor; (4) PD1/L1 inhibitor and tyrosine kinase …

tyrosine
vegf
growth factors
cancer
chemotherapy regimen
  • 0 views
  • 12 Nov, 2021
  • 3 locations
None
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.

metastasis
cancer
bladder tumor
triple negative breast cancer
alopecia
  • 0 views
  • 10 Oct, 2021
  • 11 locations
None
Familial Investigations of Childhood Cancer Predisposition

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic …

genetic testing
biological factors
childhood cancer
familial cancer
cancer
  • 213 views
  • 21 May, 2021
  • 1 location